Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Use of Droplet Digital PCR (ddPCR) for Absolute Quantification of Viral Shedding in EMA Submissions

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Use of Droplet Digital PCR (ddPCR) for Absolute Quantification of Viral Shedding in EMA Submissions

Absolute Quantification of Viral Shedding via ddPCR for EMA Submissions

CELL & GENE | RNA | BIOLOGICS

  • Precision in every partition: Defensible viral shedding data for European regulatory authorities.*

    • What is the primary advantage of ddPCR over qPCR for viral shedding analysis?

    A: Droplet Digital PCR (ddPCR) provides absolute quantification of nucleic acids without requiring a standard curve. This eliminates the variability associated with standard curve generation and offers superior precision and day-to-day reproducibility, which is a significant advantage for longitudinal shedding studies.

    How does ddPCR meet EMA’s expectations for biodistribution and shedding studies?

    A: European regulatory authorities expect robust, quantitative data to accurately assess the risk of vector transmission. ddPCR delivers absolute copy number data (e.g., vector copies per mL of plasma), providing a definitive measure that directly supports environmental risk assessments and strengthens the overall safety profile within a regulatory submission.

    Can ddPCR differentiate between the vector sequence and homologous endogenous sequences?

    A: Yes. The specificity of ddPCR is determined by the primer and probe design. Franklin Biolabs develops and validates GxP-compliant assays with high specificity to ensure that only the intended vector sequence is amplified and quantified, preventing false positives from related endogenous DNA.

    What sample types are compatible with ddPCR for shedding analysis?

    A: The method is compatible with a wide range of biological matrices relevant to shedding studies, including urine, saliva, blood (plasma, serum, whole blood), feces, and samples collected via nasal or rectal swabs. Our bioanalytical teams have extensive experience with matrix-specific nucleic acid extraction protocols.

For AAV gene therapy programs targeting EMA approval, Droplet Digital PCR (ddPCR) is the definitive method for viral shedding analysis. It provides absolute quantification of vector DNA in diverse biological matrices, directly addressing the EMA’s stringent requirements for environmental risk assessment. This approach overcomes the inherent limitations of relative quantification by qPCR, generating highly precise and reproducible data that strengthens the nonclinical safety package and de-risks the path to clinical trial authorization.

The Regulatory Requirement for Absolute Quantification

Shedding and biodistribution studies are required components of the nonclinical safety program for any viral vector-based therapeutic. For submissions to the EMA, the expectation for data integrity is exceptionally high. Regulatory reviewers require unambiguous, quantitative data to model the potential for vector transmission. Traditional qPCR, which provides relative quantification against a standard curve, can introduce variability that complicates interpretation.

ddPCR resolves this challenge by partitioning a sample into thousands of nano-liter sized droplets. Following PCR amplification, the droplets are read as either positive or negative for the target sequence. This binary outcome allows for the calculation of the absolute concentration of the target nucleic acid using Poisson statistics, removing reliance on a standard curve and yielding more precise data.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Technical Comparison: ddPCR vs. qPCR for Viral Shedding

The technical advantages of ddPCR for quantifying AAV vector DNA are well-documented. Research confirms its capacity for improved precision and robustness in determining vector DNA titers, a direct parallel to the requirements of a shedding study (PMID: 24328707). At Franklin Biolabs, our >100,000 sq ft GxP-compliant facility is equipped with advanced ddPCR platforms from Bio-Rad to execute these demanding bioanalytical assays.

Parameter Droplet Digital PCR (ddPCR) Quantitative PCR (qPCR)
Quantification Method Absolute (concentration) Relative (to standard curve)
Standard Curve Not required Required
Precision High; less susceptible to PCR efficiency Moderate; dependent on standard curve quality
Inhibitor Tolerance Higher tolerance due to partitioning Lower tolerance; inhibitors can affect Cq values

De-Risking Clinical Development Timelines

Adopting a superior bioanalytical method early in development has direct strategic benefits. The robust, absolute data generated by ddPCR provides a clear and defensible safety profile, reducing the likelihood of regulatory questions that can delay clinical trial initiation. This commitment to data quality is a core component of our approach, which has supported an 18-24 month average IND timeline for our partners. Since 2019, programs we have supported have achieved a 100% IND success rate, a record we are proud to continue since the Franklin Biolabs brand launched in 2024.

The principle of using the best available quantitative tool is a consistent theme in advanced therapeutic development. For instance, the use of non-destructive reporter genes to quantify gene transfer in vivo demonstrates the value of obtaining clear, direct measurements to guide program decisions (PMID: 16390274). Similarly, ddPCR provides that same level of quantitative clarity for the key safety question of viral shedding, strengthening the entire regulatory submission.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities